title: Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
abstract: BACKGROUND
  The Pneumonia Severity Index (PSI) has been advocated as an objective measure of risk stratification to help determine the initial site of treatment for patients with community-acquired pneumonia.
  
  
  OBJECTIVE
  To determine whether outpatient care of PSI-defined low-risk patients with community-acquired pneumonia is as safe and effective as hospitalization.
  
  
  METHODS
  Unblinded, randomized, controlled trial.
  
  
  METHODS
  2 tertiary care hospitals.
  
  
  METHODS
  224 immunocompetent adults in risk class II or III (PSI scores <or=90 points) who received a diagnosis of community-acquired pneumonia in the emergency department and had no extenuating circumstances.
  
  
  METHODS
  Outpatient care with oral levofloxacin therapy or hospitalization with sequential intravenous and oral levofloxacin therapy.
  
  
  METHODS
  The primary end point was the percentage of patients with an overall successful outcome at the end of treatment, according to 7 predefined criteria. Secondary end points included patients' quality of life and satisfaction.
  
  
  RESULTS
  Overall successful outcome was achieved in 83.6% of outpatients and 80.7% of hospitalized patients (absolute difference, 2.9 percentage points [95% CI, -7.1 to 12.9 percentage points]). More outpatients were satisfied with their overall care (91.2% vs. 79.1%; absolute difference, 12.1 percentage points [CI, 1.8 to 22.5 percentage points]). Quality of life and the percentages of patients with adverse drug reactions (9.1% vs. 9.6%), medical complications (0.9% vs. 2.6%), subsequent hospital admissions (6.3% vs. 7.0%), and overall mortality (0.9% vs. 0%) were similar in the outpatient and hospitalization groups.
  
  
  CONCLUSIONS
  The power to detect a serious complication, such as death, was limited given the relatively small sample size.
  
  
  CONCLUSIONS
  In selected patients who had community-acquired pneumonia, PSI risk class II and III, and were treated with levofloxacin, outpatient care in the absence of respiratory failure, unstable comorbid conditions, complicated pleural effusions, and social problems was as safe and effective as hospitalization and provided greater patient satisfaction.
authors.affiliation: IDIBELL-Hospital Universitari de Bellvitge, University of Barcelona, and SCIAS-Hospital de Barcelona, Barcelona, Spain. jcarratala@wanadoo.es <jcarratala@wanadoo.es>
authors.forename: Jordi
authors.initials: J
authors.lastname: Carratalà
authors.forename: Núria
authors.initials: N
authors.lastname: Fernández-Sabé
authors.forename: Lucía
authors.initials: L
authors.lastname: Ortega
authors.forename: Xavier
authors.initials: X
authors.lastname: Castellsagué
authors.forename: Beatriz
authors.initials: B
authors.lastname: Rosón
authors.forename: Jordi
authors.initials: J
authors.lastname: Dorca
authors.forename: Ana
authors.initials: A
authors.lastname: Fernández-Agüera
authors.forename: Ricard
authors.initials: R
authors.lastname: Verdaguer
authors.forename: Joaquín
authors.initials: J
authors.lastname: Martínez
authors.forename: Frederic
authors.initials: F
authors.lastname: Manresa
authors.forename: Francesc
authors.initials: F
authors.lastname: Gudiol
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000592:standards*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D017714:Community-Acquired Infections / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D007262:Infusions, Intravenous; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*; D017063:Outcome Assessment, Health Care; D017060:Patient Satisfaction; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011788:Quality of Life; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin